Dr. Khanna has over 20 years of experience utilizing a variety of biophysical tools, including In silico docking, Surface Plasmon Resonance (SPR), Nuclear Magnetic Resonance (NMR), and X-ray Crystallography, to study protein-protein, protein-RNA, and protein-small molecule interactions. Her research has significantly advanced the understanding of these interactions, contributing to the development of novel therapeutics for neurodegenerative diseases. Recently, her lab's discoveries have led to the formation of several startup companies focused on developing small molecules for neurodegenerative diseases, all co-founded with her postdoctoral fellows, which is a source of great pride.